Physician profile
Michael A Hait
NPI 1326028085
$7,974.92
in general payments reported to CMS, 2019-2025
20 companies · $2,314 in 2025
The $2,314 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $603 · 2021: $986 · 2022: $1,011 · 2023: $686 · 2024: $2,203 · 2025: $2,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,070 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,069.85 |
| Education | $132.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,887.48 | 2019-2025 | |
| Amgen INC. | $1,801.36 | 2019-2025 | Enbrel, Tavneos, Evenity |
| Janssen Biotech, INC. | $1,070.13 | 2021-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $426.58 | 2020-2025 | Saphnelo |
| Lilly USA, LLC | $331.00 | 2019-2023 | Taltz |
| Ucb, INC. | $330.54 | 2023-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $216.53 | 2024-2025 | |
| Hikma Pharmaceuticals USA | $169.48 | 2020-2021 | |
| Glaxosmithkline, LLC. | $153.72 | 2021-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $147.45 | 2019-2025 | Orencia |
| Fresenius Kabi USA, LLC | $96.07 | 2024-2025 | Idacio |
| Sandoz INC. | $54.88 | 2024-2025 | Hyrimoz |
| Pfizer INC. | $52.03 | 2019-2023 | |
| Sobi, INC | $44.24 | 2024-2025 | |
| Horizon Therapeutics Plc | $43.93 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $37.44 | 2025 | Tonmya |
| Novartis Pharmaceuticals Corporation | $33.72 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $32.80 | 2025 | Opsynvi |
| Scilex Pharmaceuticals INC. | $24.84 | 2024 | |
| Alexion Pharmaceuticals, INC. | $20.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hait listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.